Free Design Audit Available - Click Here for Details

FDA clears IceCure Medical’s next-gen single-probe cryoablation system

IceCure Medical (Nasdaq:ICCM) announced today that the FDA granted clearance for its next-generation single-probe cryoablation system

The XSense cryoablation system with CryoProbes received clearance for all indications for which the company’s ProSense system already holds FDA clearance. That includes minimally invasive cryoablation in general surgery, dermatology and neurology, including cryoanalgesia. It also covers thoracic surgery, ENT, gynecology, oncology, proctology and urology.

Caesarea, Israel-based IceCure designed the system to destroy tissue by applying extreme cold temperatures. Targets include fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions and warts.

Sign up for Blog Updates